title: [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
abstract: OBJECTIVE
  Extraovarian peritoneal serous papillary carcinoma (EPSPC) is both histologically and clinically similar to stage III-IV ovarian papillary serous carcinoma (OPSC). The purpose of this study is to investigate the clinical findings, treatment, and outcome of EPSPC patients compared with stage III-IV OPSC patients.
  
  
  METHODS
  The data of 12 EPSPC patients and 45 stage III-IV OPSC patients were retrospectively reviewed, comparing the characteristics on clinical presentation and treatment, sensitivity to first-line chemotherapy agents and survival.
  
  
  RESULTS
  By analysis of patients' characteristics, presenting signs and symptoms, type and extent of surgery, tumor response to first-line chemotherapy, recurrence-free interval, recurrence site and serum CA-125 levels, no significant difference was observed between the EPSPC patients and stage III-IV OPSC controls. The prevailing presenting symptoms were abdominal mass and ascites. The mainstay of treatment was debulking surgery followed by adjuvant platinum-based chemotherapy. The complete clinical response of stage III-IV OPSC was 91.8% compared with 25.0% for women with EPSPC (P < 0.01).
  
  
  CONCLUSIONS
  The clinical and surgical characteristics of EPSPC are similar to those of stage III-IV OPSC. When the same treatment strategy is applied, similar response and survival are expected in either condition.
authors.affiliation: Department of Gynecology and Oncology, Oncology Hospital, Peking University School of Oncology, Beijing 100036, China. gaoyunong@vip.sina.com
authors.forename: Yu-Nong
authors.initials: YN
authors.lastname: Gao
authors.forename: Jing-Xian
authors.initials: JX
authors.lastname: Liu
authors.forename: Wen
authors.initials: W
authors.lastname: Wang
authors.forename: Wei-Fan
authors.initials: WF
authors.lastname: Li
authors.forename: Wang-Shu
authors.initials: WS
authors.lastname: Tang
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D018283:Cystadenocarcinoma, Papillary / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel; D010534:Peritoneal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D018394:CA-125 Antigen; D043823:Taxoids; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin